Merck’s glorious victory in lung cancer marks a Russian winter for Bristol-Myers
Sunday was checkpoint inhibitor day at ESMO, with the three big players now in the market outlining how they’re lining up in the blockbuster field …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
